Breaking News
July 19, 2018 - Compounds found in green tea and wine may block formation of toxic metabolites
July 19, 2018 - Gene regulator associated with protein pileup in exfoliation glaucoma
July 19, 2018 - Trump administration summons immigrant infants
July 19, 2018 - FDA grants approval for first breast cancer drug through ‘Real-Time Oncology Review’
July 19, 2018 - Five tips for men seeking plastic surgery
July 19, 2018 - Researchers discover the reasons why some people get dizzy when hearing certain sounds
July 19, 2018 - Research project investigates snake venom treatment as antibiotic alternative for eye infections
July 19, 2018 - Melanoma could soon be detected using a blood test
July 19, 2018 - Exposure to bright light may have big impact on sleep-related behavior in children
July 19, 2018 - Deleting single gene in gut bacteria affects metabolism, reduces weight gain in mice
July 19, 2018 - New proteomics studies help gain more insights into Alzheimer’s, cancer and listeriosis
July 19, 2018 - Study finds major discrepancies in prescription drug labeling pregnancy information across four countries
July 19, 2018 - Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 19, 2018 - Watching the immune system in action reveals what happens when things goes wrong
July 19, 2018 - Increasing blood sugar levels improves memory and performance in older adults
July 19, 2018 - Connection between self-regulation and obesity appears to be different for girls and boys
July 19, 2018 - Researchers develop new, less destructive method for whitening teeth
July 19, 2018 - Revving up innate control of viral infection requires a three-cell ignition
July 19, 2018 - Inaccurate direct-to-consumer raw genetic data can harm patients, new research suggests
July 19, 2018 - Weight loss surgery is effective under the right situations
July 19, 2018 - BioTek awarded patent for autofocus feature on microplate reader
July 19, 2018 - Low-carb diets reduce stiffness of arteries in women and promote weight loss in men
July 19, 2018 - New review examines cannabinoids’ potential for direct treatment of cancer
July 19, 2018 - Allergic responses may help protect the skin against cancer, research suggests
July 19, 2018 - Inappropriate Prescribing of Abx High in Urgent Care Centers
July 19, 2018 - Many at risk for HIV despite lifesaving pill
July 19, 2018 - Tips for doctors and parents on the harms of marijuana use for teens
July 18, 2018 - Researchers detect presence of IgE antibodies after kidney transplantation
July 18, 2018 - New technique allows researchers to create large scale, personalized bone grafts
July 18, 2018 - Smoking May Boost Atrial Fibrillation Risk
July 18, 2018 - Genome editing method targets AIDS virus
July 18, 2018 - These things matter: Medical complications are not inevitable, a physician writes
July 18, 2018 - Cognitive functions often wilt as water departs the body, shows study
July 18, 2018 - Origins of bread found 14,400 years ago in Jordan
July 18, 2018 - Low-dose ketamine found to be as effective as opioids for treating acute pain
July 18, 2018 - Novel bioengineering technique could help repair bone defects
July 18, 2018 - Researchers identify new potential target protein for colon cancer
July 18, 2018 - Air pollution contributes significantly to diabetes globally
July 18, 2018 - Cell membrane’s importance offers new strategy to fight infections
July 18, 2018 - Researchers identify key protein involved in irregular brain cell activity
July 18, 2018 - 3D modeling of drug resistance could lead to more effective cancer treatment
July 18, 2018 - Hunger hormones could be key to new treatments for drug, alcohol addiction
July 18, 2018 - Nitrate-cured meats may contribute to mania, study finds
July 18, 2018 - Why men may recover more quickly from influenza infections than women
July 18, 2018 - Study finds discharge against medical advice as predictor of readmissions in heart attack patients
July 18, 2018 - KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
July 18, 2018 - Self-control and obesity: Gender matters in children
July 18, 2018 - Bioengineers, diabetes researchers convene to discuss future concepts for precision medicine
July 18, 2018 - New findings support more conservative use of ED neuroimaging for non-index seizures
July 18, 2018 - Practicing yoga benefits pregnant women, study suggests
July 18, 2018 - New strategy may lead to more accurate breast cancer diagnoses
July 18, 2018 - FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
July 18, 2018 - New guide helps hospitals pick right partner to handle hospitalist services
July 18, 2018 - Deep data dive helps predict cerebral palsy
July 18, 2018 - Stricter firearm legislation associated with reduced murder and suicide rates
July 18, 2018 - Physical and sexual abuse in childhood associated with endometriosis risk
July 18, 2018 - Omega 3 supplements do not reduce risk of heart disease, stroke or death
July 18, 2018 - GSA’s new publication provides support for safe use of OTC analgesics by older adults
July 18, 2018 - Researchers receive grant from U.S. Department of Education to study children with HFASD
July 18, 2018 - Early childhood adversity increases sensitivity of the body’s immune response to cocaine
July 18, 2018 - Parental incarceration affects health behaviors of children in adulthood
July 18, 2018 - Researchers find that yellow fever and Asian tiger mosquitoes can carry new virus
July 18, 2018 - Two Regimens Fail to Stop Declines in β-Cell Function
July 18, 2018 - Researchers apply computing power to track the spread of cancer
July 18, 2018 - Olfactory receptors play pathophysiological role in all organs than merely smell perception
July 18, 2018 - Fish consumption associated with lower risk of early death
July 18, 2018 - MR Solutions’ 7T MRI imaging system installed at University of Hawaii
July 18, 2018 - Humorous ads screened around World Cup game achieve higher biometric response than sporty ads
July 18, 2018 - New study demonstrates little effect of hormone therapy on artery thickness
July 18, 2018 - A 3-Pronged Plan to Cut Type 2 Diabetes Risk
July 18, 2018 - New clues to sepsis may speed diagnosis
July 18, 2018 - Stars of Stanford Medicine: Improving cardiovascular health in Africa and beyond
July 18, 2018 - Heart attack risk continues to increase among pregnant women, study finds
July 18, 2018 - Few tips to help avoid sunburns in summer
July 18, 2018 - High-fat diet and systemic inflammation contribute to progression of prostate cancer
July 18, 2018 - Researchers develop 3D map of gene interactions that play key role in heart disease
July 18, 2018 - Conservative management of lung subsolid nodules reduces overtreatment and unnecessary surgery
July 18, 2018 - Report warns of dog illness that can spread to owners
July 18, 2018 - A winning essayist’s tips for keeping track of scientific facts
July 18, 2018 - Researchers seek to understand role of APOE mutation in Alzheimer’s disease
FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

image_pdfDownload PDFimage_print

KENILWORTH, N.J.–(BUSINESS WIRE) June 13, 2018 –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. This indication is approved under the FDA’s accelerated approval regulations based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Keytruda is not recommended for the treatment of patients with PMBCL who require urgent cytoreductive therapy. With this indication, Keytruda becomes the first anti-PD-1 therapy to be approved for the treatment of PMBCL, a type of non-Hodgkin lymphoma. This is the second indication for Keytruda for the treatment of a hematologic malignancy.

“Relapsed or refractory PMBCL is often a challenging disease to treat, and many affected patients are young adults,” said Philippe Armand, M.D., Ph.D., medical oncologist in the Hematologic Oncology Treatment Center at Dana-Farber Cancer Institute. “In the clinical trial that supported this approval, treatment with Keytruda resulted in meaningful responses, including complete disease remission in some patients. This approval therefore provides another therapeutic option for patients with PMBCL who have progressed on or after prior therapies.”

Immune-mediated adverse reactions occurred with Keytruda, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions and solid organ transplant rejection. Based on the severity of the adverse reaction, Keytruda should be withheld or discontinued and corticosteroids administered if appropriate. Immune-mediated complications, including fatal events, occurred in patients with classical Hodgkin lymphoma (cHL) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with Keytruda. Follow patients closely for early evidence of transplant-related complications, and intervene promptly. In patients with a history of allogeneic HSCT, acute graft-versus-host disease (GVHD), including fatal GVHD, has been reported after treatment with Keytruda; consider the benefit of Keytruda versus the risk of GVHD. Keytruda can also cause severe or life-threatening infusion-related reactions. Monitor patients for signs and symptoms of infusion-related reactions; for Grade 3 or 4 reactions, stop infusion and permanently discontinue Keytruda. Based on its mechanism of action, Keytruda can cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised of the potential hazard to a fetus.

“The approval of our anti-PD-1 therapy, Keytruda, for the treatment of refractory or relapsed PMBCL provides an important therapeutic option for patients who have this rare disease,” said Jonathan Cheng, M.D., vice president, oncology clinical research, Merck Research Laboratories. “This approval reinforces Merck’s commitment to helping patients diagnosed with hematologic cancers and marks the second indication for Keytruda in a hematologic malignancy.”

Data Supporting the Approval

The approval was based on data from KEYNOTE-170, a multicenter, open-label, single-arm trial evaluating Keytruda in 53 patients with relapsed or refractory PMBCL. Patients were not eligible for the trial if they had active non-infectious pneumonitis, allogeneic HSCT within the past five years (or greater than 5 years but with symptoms of GVHD), active autoimmune disease, a medical condition that required immunosuppression, or an active infection requiring systemic therapy. Patients received Keytruda 200 mg every three weeks until unacceptable toxicity or documented disease progression, or for up to 24 months for patients who did not progress. Disease assessments were performed every 12 weeks and assessed by blinded independent central review according to the 2007 revised International Working Group criteria. Efficacy was based on overall response rate (ORR) and duration of response (DOR).

Among the 53 patients accrued in KEYNOTE-170, the baseline characteristics were: median age of 33 years (range, 20 to 61 years); 43 percent were male; 92 percent were White; 43 percent had an ECOG performance status (PS) of 0 and 57 percent had an ECOG PS of 1. The median number of prior lines of therapy administered for the treatment of PMBCL was three (range, 2 to 8). Thirty-six percent had primary refractory disease, 49 percent had relapsed disease refractory to the last prior therapy, and 15 percent had untreated relapse. Twenty-six percent of patients had undergone prior autologous HSCT and 32 percent of patients had prior radiation therapy. All patients had received rituximab as part of a prior line of therapy.

In KEYNOTE-170, the ORR was 45 percent (95% CI, 32, 60), with a complete response rate (CRR) of 11 percent and a partial response rate of 34 percent. Median DOR, based on 24 patients who responded, was not reached (range, 1.1+ to 19.2+ months). For the 24 responders, the median time to first objective response (complete or partial response) was 2.8 months (range, 2.1 to 8.5 months). Median follow-up time was 9.7 months.

Among the 53 patients with PMBCL treated in KEYNOTE-170, Keytruda was discontinued due to adverse reactions in eight percent of patients, and treatment was interrupted due to adverse reactions in 15 percent. Twenty-five percent of patients had an adverse reaction requiring systemic corticosteroid therapy. Serious adverse reactions occurred in 26 percent of patients, and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%) and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (occurring in ≥20% of patients) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%) and dyspnea (21%).

There is limited experience with Keytruda in pediatric patients. Efficacy for pediatric patients with PMBCL was extrapolated from the results in the adult PMBCL population. In a study of 40 pediatric patients with advanced melanoma, lymphoma, or PD-L1 positive advanced, relapsed, or refractory solid tumors, patients were administered Keytruda 2 mg/kg every three weeks. Patients received Keytruda for a median of three doses (range, 1-17 doses), with 34 patients (85%) receiving Keytruda for two doses or more. The safety profile in these pediatric patients was similar to that seen in adults treated with Keytruda. Toxicities that occurred at a higher rate (≥15% difference) in pediatric patients when compared to adults under 65 years of age were fatigue (45%), vomiting (38%), abdominal pain (28%), hypertransaminasemia (28%) and hyponatremia (18%).

Merck’s Focus on Cancer

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment.

As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers.

For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.

About the Merck Access Program for Keytruda

At Merck, we are committed to supporting accessibility to our cancer medicines. Merck provides multiple programs to help ensure that appropriate patients who are prescribed Keytruda have access to our anti-PD-1 therapy. The Merck Access Program provides reimbursement support for patients receiving Keytruda, including information to help with out-of-pocket costs and co-pay assistance for eligible patients. Merck also offers free product through our patient assistance program to eligible patients, primarily the uninsured, who, without our assistance, could not afford their medicine. More information is available by calling 855-257-3932 or visiting www.merckaccessprogram-keytruda.com.

About Merck’s Patient Support Program for Keytruda

Merck is committed to helping provide patients and their caregivers support throughout their treatment with Keytruda. The KEY+YOU Patient Support Program provides a range of resources and services. For further information and to sign up, patients and physicians may call 85-KEYTRUDA (855-398-7832) or visit www.keytruda.com.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Source: Merck

Posted: June 2018

Related Articles:

  • FDA Approves Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 – June 12, 2018
  • FDA Approves Merck’s Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 – September 22, 2017
  • FDA Approves Keytruda (pembrolizumab) as First Cancer Treatment for any Solid Tumor with a Specific Genetic Feature – May 23, 2017
  • FDA Approves Merck’s Keytruda (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma – May 18, 2017
  • FDA Approves Merck’s Keytruda (pembrolizumab) as First-Line Combination Therapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression – May 10, 2017
  • FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL) – March 15, 2017
  • FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer – October 24, 2016
  • FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – August 5, 2016
  • FDA Approves Expanded Indication for Keytruda (pembrolizumab) for the Treatment of Patients with Advanced Melanoma – December 18, 2015
  • FDA Approves Keytruda (pembrolizumab) for Advanced Non-Small Cell Lung Cancer – October 2, 2015
  • FDA Approves Keytruda (pembrolizumab) for Advanced Melanoma – September 4, 2014
  • Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab – September 2, 2014
  • Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for Advanced Melanoma – June 30, 2014

Keytruda (pembrolizumab) FDA Approval History

Tagged with:

About author

Related Articles